Clinical Trials Logo

Intrahepatic Cholangiocarcinoma clinical trials

View clinical trials related to Intrahepatic Cholangiocarcinoma.

Filter by:

NCT ID: NCT02762721 Completed - Cholangiocarcinoma Clinical Trials

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

Start date: June 6, 2016
Phase: N/A
Study type: Observational

The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples

NCT ID: NCT02588755 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection

Start date: December 2015
Phase: N/A
Study type: Interventional

The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection

NCT ID: NCT02526771 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma

Start date: August 2015
Phase: N/A
Study type: Interventional

The aim of this study is to compare the surgical outcomes of conventional lymph node dissection with unconventional lymph node dissection during resection of Intrahepatic cholangiocarcinoma.

NCT ID: NCT02512692 Active, not recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

Start date: July 21, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of 90 Y TARE (Y90) in combination with gemcitabine and cisplatin in patients with unresectable intrahepatic cholangiocarcinoma (ICC).

NCT ID: NCT02415036 Terminated - Clinical trials for Hepatocellular Carcinoma

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Start date: June 2014
Phase: Phase 2
Study type: Interventional

This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to the liver.

NCT ID: NCT02273739 Completed - Solid Tumor Clinical Trials

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Start date: December 8, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an isocitrate dehydrogenase-2 (IDH2) mutation.

NCT ID: NCT02254681 Terminated - Clinical trials for Intrahepatic Cholangiocarcinoma

Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The overall goal of this study is to determine the safety and efficacy of combination treatment of low-dose fractionated radiation therapy with gemcitabine-cisplatin chemotherapy for locally advanced mass forming intra-hepatic cholangiocarcinoma.

NCT ID: NCT02238613 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer

Start date: August 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether radioactive stents and common used plastic stents are effective and safety in the treatment of unresectable biliary tract cancer.

NCT ID: NCT02184871 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Next Generation Sequencing in Intrahepatic Cholangiocarcinoma

EtherBil
Start date: May 2014
Phase: N/A
Study type: Observational

The aim of the present study is to perform a comprehensive molecular characterization of intrahepatic cholangiocarcinoma (ICC) in patients exposed to well-known or putative risk factors (such as asbestos) for this malignancy, in order to identify possible "molecular signatures" associated to such different risk factors.

NCT ID: NCT01954745 Active, not recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This research study is evaluating a drug called cabozantinib as a possible treatment cancer of the bile duct. Cabozantinib is a drug that targets specific pathways inside the cells of the body. By blocking the c-MET and VEGFR2 pathways from sending signals, cabozantinib may prevent cells from multiplying. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to stop the growth of bile duct cancer. In this research study, the investigators are looking to see how well cabozantinib works in slowing the growth of bile duct cancer. The investigators are also assessing the safety and tolerability of cabozantinib in participants with this type of cancer.